Gresonitamab

格瑞妥单抗

Report date: 2026/03/19 17:03:53

Base Information

Drug NameGresonitamab

Drug Alias NameCLDN18.2-HLE-BiTEAMG-910

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionAnti-CLDN18T-cell surface glycoprotein CD3 epsilon chain modulators

TargetsClaudin-18 splice variant 2T-cell surface glycoprotein CD3 epsilon chain

Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanNetherlands +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesAmgen Inc

Active IndicationsStomach Neoplasms

Inactive IndicationsEsophageal NeoplasmsAdenocarcinoma

Other Information

ATC CodeN/A